CoChat

Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Lubiprostone is a ClC-2 chloride channel activator approved for the treatment of chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) in adults and irritable bowel syndrome with constipation (IBS-C) in women. Lubiprostone is generally well tolerated, with nausea being the most common adverse event. AIMS: To characterize nausea with lubiprostone using pooled results from clinical studies in patients with CIC, OIC, or IBS-C. METHODS: Data from three 3- and 4-week placebo-controlled studies and three long-term open-label studies were pooled for the CIC analysis. The OIC and IBS-C analyses each used pooled data from three 12-week placebo-controlled studies and one 36-week open-label extension study. RESULTS: The populations included the following numbers of patients: CIC, 316 (placebo) and 1113 (lubiprostone 24 mcg twice daily [BID]); OIC, 652 (placebo) and 889 (lubiprostone 24 mcg BID); and IBS-C, 435 (placebo) and 1011 (lubiprostone 8 mcg BID). The incidence of nausea in lubiprostone-treated patients ranged from 11.4 to 31.1%, with the highest incidence in patients with CIC. Among patients with any nausea, most reported only mild or moderate severity (96.5-99.1% across indications) and only one event (83.6-88.7%); most events occurred within the first 5 days of treatment. CONCLUSIONS: Nausea was the most common adverse event following the treatment with lubiprostone. Event rates varied by indication and dose, and the majority of nausea adverse events were mild to moderate in severity. Nausea events predominantly occurred early in the treatment period in all of the pooled study populations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10620-017-4680-1

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Treatment continuation among lubiprostone-treated patients who reported only one AE of nausea in the a chronic idiopathic constipation, b opioid-induced constipation, and c irritable bowel syndrome with constipation studies. AE adverse event
Fig. 1 Treatment continuation among lubiprostone-treated patients who reported only one AE of nausea in the a chronic idiopathic constipation, b opioid-induced constipation, and c irritable bowel syndrome with constipation studies. AE adverse eventCC BY-NC · PubMed Central
Fig. 2 Cumulative incidence of events of nausea in lubiprostone-treated patients in randomized controlled trials. The solid line denotes CIC, the dashed line denotes OIC, and the dash-dotted line denotes IBS-C. CIC chronic idiopathic constipation, IBS-C irritable bowel syndrome with constipation, OIC opioid-induced constipation
Fig. 2 Cumulative incidence of events of nausea in lubiprostone-treated patients in randomized controlled trials. The solid line denotes CIC, the dashed line denotes OIC, and the dash-dotted line denotes IBS-C. CIC chronic idiopathic constipation, IBS-C irritable bowel syndrome with constipation, OIC opioid-induced constipationCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 46

Metadata

Authors
Cryer, B., Drossman, D. A., Chey, W. D., Webster, L., Habibi, S., & Wang, M.
Affiliations
  • VA North Texas Health Care System (US)
  • University of North Carolina at Chapel Hill (US)
  • University of Michigan (US)
  • PRA Health Sciences (US)
Corresponding author
Cryer, Byron
Venue
Digestive Diseases and Sciences
Published
2017-08-28
Volume
62
Issue
12
Pages
3568-3578
ISSN
  • 0163-2116 (ISSN-L)
  • 1573-2568
OpenAlex
W2748730319
Cited by
43
References
34
Citations by year
2026: 2 · 2025: 3 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 9 · 2019: 6 · 2018: 5 · 2017: 2
FWCI
6.30
Type
journal article
Language
en
Open access
Locations
  • Digestive Diseases and Sciences (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • UNC Libraries
Funders
  • Sucampo Pharma Americas, LLC
  • Takeda Pharmaceuticals International
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Surgery › Nausea and vomiting management
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
lubiprostone, nausea, adverse events, chronic idiopathic constipation, opioid-induced constipation, irritable bowel syndrome with constipation, drug safety
MeSH terms
Lubiprostone, Constipation, Humans, Nausea, Chloride Channel Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders. https://app.cochat.ai/papers/10.1007/s10620-017-4680-1
The paper
Cryer, B., Drossman, D. A., Chey, W. D., Webster, L., Habibi, S., & Wang, M. (2017). Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-017-4680-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.